Abstract
The signaling pathways that determine the fate of a cell regarding death or survival depend on a large number of regulatory proteins. The Bax Inhibitor-1 (BI-1) family is a highly preserved family of small transmembrane proteins located mostly in the endoplasmic reticulum (ER). Although most members of this family are still not characterized an antiapoptotic effect has been described for BI-1, Lifeguard (LFG), and the Golgi anti-apoptotic protein (GAAP). The cytoprotective activity has been associated to the control of ion homeostasis and ER stress but includes other cell death stimuli as well. Recent data describes multiple interactions between the proteins of the BI-1 family and the Bcl-2 family either stimulating the antiapoptotic function of Bcl-2 or inhibiting the proapoptotic effect of Bax. The potent cell death suppression makes this protein family an interesting target for the development of new drugs and gene therapeutic approaches for diseases caused by apoptotic dysregulation, such as cancer.
Keywords: Protein family, Bax-inhibitor, programmed cell death, apoptosis inhibitors, transmembrane protein, cancer
Current Molecular Medicine
Title: The Bax Inhibitor-1 (BI-1) Family in Apoptosis and Tumorigenesis
Volume: 8 Issue: 2
Author(s): Kerstin Reimers, Claudia Y.U. Choi, Vesna Bucan and Peter M. Vogt
Affiliation:
Keywords: Protein family, Bax-inhibitor, programmed cell death, apoptosis inhibitors, transmembrane protein, cancer
Abstract: The signaling pathways that determine the fate of a cell regarding death or survival depend on a large number of regulatory proteins. The Bax Inhibitor-1 (BI-1) family is a highly preserved family of small transmembrane proteins located mostly in the endoplasmic reticulum (ER). Although most members of this family are still not characterized an antiapoptotic effect has been described for BI-1, Lifeguard (LFG), and the Golgi anti-apoptotic protein (GAAP). The cytoprotective activity has been associated to the control of ion homeostasis and ER stress but includes other cell death stimuli as well. Recent data describes multiple interactions between the proteins of the BI-1 family and the Bcl-2 family either stimulating the antiapoptotic function of Bcl-2 or inhibiting the proapoptotic effect of Bax. The potent cell death suppression makes this protein family an interesting target for the development of new drugs and gene therapeutic approaches for diseases caused by apoptotic dysregulation, such as cancer.
Export Options
About this article
Cite this article as:
Reimers Kerstin, Choi Y.U. Claudia, Bucan Vesna and Vogt M. Peter, The Bax Inhibitor-1 (BI-1) Family in Apoptosis and Tumorigenesis, Current Molecular Medicine 2008; 8 (2) . https://dx.doi.org/10.2174/156652408783769562
DOI https://dx.doi.org/10.2174/156652408783769562 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Radiogenetic Therapy: Strategies to Overcome Tumor Resistance
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Drug Therapy Ferroptosis: A Trusted Ally in Combating Drug Resistance in Cancer
Current Medicinal Chemistry Curcumin: A Natural Product for Diabetes and its Complications
Current Topics in Medicinal Chemistry Development of Cisplatin Nanoparticles as Dry Powder Inhalers for Lung Cancer
Current Nanoscience miRNA and Proteomic Dysregulation in Non-Small Cell Lung Cancer in Response to Cigarette Smoke
MicroRNA Targeting Kruppel-Like Factor 5 (KLF5) for Cancer Therapy
Current Topics in Medicinal Chemistry Serum Biochemical Markers of Brain Injury
Mini-Reviews in Medicinal Chemistry Biologics for ANCA-Associated Vasculitis
Inflammation & Allergy - Drug Targets (Discontinued) ADAM10 as a Therapeutic Target for Cancer and Inflammation
Current Pharmaceutical Design Emerging Insights in the Role of Tissue Factor in Cancer
Current Genomics Contextualizing the Genes Altered in Bladder Neoplasms in Pediatric and Teen Patients Allows Identifying Two Main Classes of Biological Processes Involved and New Potential Therapeutic Targets
Current Genomics A Network Pharmacology Approach to Reveal the Underlying Mechanisms of Zuogui Yin in the Treatment of Male Infertility
Combinatorial Chemistry & High Throughput Screening Bugs as Drugs: Understanding the Linkage between Gut Microbiota and Cancer Treatment
Current Drug Targets Preclinical and Clinical Studies on the Use of Stem Cells for Bone Repair: A Systematic Review
Current Stem Cell Research & Therapy The Endothelin Axis as Therapeutic Target in Human Malignancies: Present and Future
Current Pharmaceutical Design Current Management of Neonatal Neuroblastoma
Current Pediatric Reviews Biomedical Applications of Poly(Lactic Acid)
Recent Patents on Regenerative Medicine Structure and Regulation of the Drug-Metabolizing Enzymes Arylamine N-acetyltransferases
Current Medicinal Chemistry Small-molecule Inhibitors of Epigenetic Mutations as Compelling Drugtargets for Myelodysplastic Syndromes
Current Cancer Drug Targets